Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

» KYTH's 10-Y Financials

Financials (Next Earnings Date: 0)

Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2015

KYTH Guru Trades in Q1 2015

George Soros 54,194 sh (New)
RS Investment Management 429,011 sh (+19.38%)
» More
Q2 2015

KYTH Guru Trades in Q2 2015

Paul Tudor Jones 6,939 sh (New)
Mario Gabelli 75,100 sh (New)
RS Investment Management Sold Out
George Soros Sold Out
» More
Q3 2015

KYTH Guru Trades in Q3 2015

Mario Gabelli 259,500 sh (+245.54%)
Paul Tudor Jones Sold Out
» More
Q4 2015

KYTH Guru Trades in Q4 2015

Mario Gabelli Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with KYTH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Traded in other countries:KYT.Germany,

KYTHERA Biopharmaceuticals Inc was incorporated in Delaware in June 2004 under the name Dermion, Inc. It commenced operations in August 2005, and it changed its name to AESTHERx, Inc. In July 2006, it changed its name to KYTHERA Biopharmaceuticals, Inc. It is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. The Company's objective is to develop first-in-class, prescription aesthetic products using an approach that relies on the scientific rigor of biotechnology to address unmet needs in the rapidly-growing market for aesthetic medicine. The Company's initial focus is on the facial aesthetics market, which comprises the majority of the aesthetic medicine market. The Company's product candidate, ATX-101, is a potential first-in-class, injectable drug in late stage clinical development for the reduction of submental fat, which commonly presents as an undesirable double chin. Based on clinical trials conducted to date, ATX-101 has exhibited significant, meaningful and long-lasting results in the reduction of submental fat.

Guru Investment Theses on KYTHERA Biopharmaceuticals Inc

Mario Gabelli Comments on Kythera Biopharmaceuticals Inc. - Oct 19, 2015

Kythera Biopharmaceuticals Inc. (NASDAQ:KYTH)(3.4%) (KYTH – $74.98 – NASDAQ), based in Westlake Village, California, is a global biopharmaceutical company that focuses on developing and commercializing medical aesthetics products. On June 17, 2015, Allergan announced that it would acquire Kythera in a merger worth $1.9 billion or $75 per share. Initially, the transaction was to be comprised of cash and stock, but on August 5, Allergan amended the terms of the offering to all cash. The transaction closed on October 1, 2015, after receiving regulatory and shareholder approvals.

From Mario Gabelli (Trades, Portfolio)'s third quarter 2015 ABC Fund commentary.

Check out Mario Gabelli latest stock trades



Buy Back


Valuation & Return


More Statistics

Revenue (TTM) (Mil) $0.29
EPS (TTM) $ -4.74
Short Percentage of Float6.97%
52-Week Range $29.86 - 76.31
Shares Outstanding (Mil)26.27
» More Articles for KYTH


Articles On GuruFocus.com
The Gabelli ABC Fund Merger and Arbitrage Shareholder Commentary for Q4 Jan 29 2016 
Mario Gabelli Comments on Kythera Biopharmaceuticals Inc. Oct 19 2015 

More From Other Websites
6 Reasons to Watch Kythera Biopharm Inc. (AGN, PFE) May 01 2016
Is Ellie Mae Inc (ELLI) A Good Stock To Buy? Dec 01 2015
Should You Buy Kennametal Inc. (KMT)? Nov 27 2015
KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement,... Oct 01 2015
KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security... Sep 28 2015
Allergan reports better-than-expected revenue Aug 06 2015
What to Expect From Allergan Earnings Aug 05 2015
These Hot Healthcare Stocks Lead Palo Alto Investors’ Picks To Big Q2 Returns Jul 17 2015
CEO Brent Saunders says Allergan remains committed to Irvine despite sale Jun 25 2015
Billionaire Mandel’s Investing Acumen Has Led Him To Williams Companies Inc and These Two Stocks Jun 22 2015
Hedge Funds Were Right About Kythera Biopharmaceuticals Inc (KYTH), Rewarded with 48% Gains Jun 17 2015
Botox maker Allergan buying Kythera, developer of double chin treatment Jun 17 2015
What Allergan Is Looking to Add With Kythera Jun 17 2015
Botox maker Allergan adds 'double-chin' drug with $2.1B deal Jun 17 2015
Botox maker Allergan adds 'double-chin' drug in $2.1B buy Jun 17 2015
Botox maker Allergan buying Kythera for $2.1 billion Jun 17 2015
Allergan to buy Kythera Biopharmaceuticals for $2.1 billion Jun 17 2015
Analyst Issues 5 Potential Biotech Buyout Candidates May 14 2015
Kythera reports 1Q loss May 07 2015
FDA approves Westlake Village company's drug to reduce double-chin fat Apr 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)